PFF In The Media

Q&A: FDA accepts IPF biomarker panel into qualification program

The FDA Center for Drug Evaluation and Research has accepted a letter of intent for the first biomarker for idiopathic pulmonary fibrosis into its Biomarker Qualification Program, according to a press release.

Link to Article

Extended-release nalbuphine lowers cough frequency in IPF-associated chronic cough

Patients with idiopathic pulmonary fibrosis-associated chronic cough who received twice-daily oral extended release nalbuphine for 6 weeks had decreases in 24-hour cough frequency, according to data published in JAMA.

Link to Article

How the PFF’s 5-year plan seeks to expand access to expert care

I’ve been writing recently about the four pillars of the Pulmonary Fibrosis Foundation’s (PFF) new five-year strategic plan introduced last year, called “The PFF Is ME.” In December, I explained the first pillar, Accelerate Research. The second pillar, Expand Access to Expert Care, is a concern for all patients in the pulmonary fibrosis (PF) community. I had the opportunity to interview the champion of the plan’s second pillar, Sonye Danoff, MD, PhD, the senior medical adviser for the PFF’s Care Center Network (CCN).

Link to Article

A first for IPF biomarkers: PROLIFIC risk score nears FDA qualification

The PROLIFIC Risk Score, a multi-biomarker blood test for idiopathic pulmonary fibrosis (IPF), has taken a significant step forward in regulatory recognition. In December 2025, the FDA’s Center for Drug Evaluation and Research accepted PROLIFIC’s Letter of Intent into its Biomarker Qualification Program; the first time an IPF biomarker has reached this milestone. This step underscores the potential of the Risk Score to improve how patients are stratified in clinical trials and how disease progression is predicted, addressing a key challenge in IPF drug development and patient care.

Link to Article

1World Radio Episode 89 - Julie Halston

Learn about Julie Halston and her late husband Ralph Howard's journey with pulmonary fibrosis, the work of the Pulmonary Fibrosis Foundation and Julie's annual event Broadway Belts for PFF. For more information about the Pulmonary Fibrosis Foundation you can go to https://www.pulmonaryfibrosis.org

Link to Article

Angiotensin-converting enzyme inhibitor use before IPF diagnosis lowers mortality risk

Chronic fatigue is a common symptom of idiopathic pulmonary fibrosis (IPF), and may affect as many as 95 percent of all individuals living with this condition. Fatigue can have a significant impact on quality of life, and it generally stems from several factors including difficulty breathing, disrupted sleep, anxiety and depression, and medications used to treat IPF.

Link to Article

6 Tips for Managing Chronic Fatigue with IPF

Chronic fatigue is a common symptom of idiopathic pulmonary fibrosis (IPF), and may affect as many as 95 percent of all individuals living with this condition. Fatigue can have a significant impact on quality of life, and it generally stems from several factors including difficulty breathing, disrupted sleep, anxiety and depression, and medications used to treat IPF.

Link to Article

DOD-funded study explores metformin as potential therapy for IPF

A clinical study led by Fernando Martinez, M.D., vice chair for clinical and translational research and academic chief of the Division of Pulmonary, Allergy and Critical Care at UMass Chan Medical School and funded by the Department of Defense (DOD) is targeting idiopathic pulmonary fibrosis (IPF).

Link to Article

4 Hidden IPF Triggers in Your Living Space

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease that causes scarring (fibrosis) of the lungs. The most common symptoms are shortness of breath and cough, and the progression of the disease varies considerably from person to person.

Link to Article

5 Ways to Manage Breathlessness and Anxiety in IPF

Breathlessness (also known as dyspnea) and anxiety are common symptoms experienced by individuals with idiopathic pulmonary fibrosis (IPF). They are also linked together in a “dyspnea-anxiety cycle.” Feeling short of breath can trigger anxiety, which can worsen your breathing and make you feel even more breathless.

Link to Article

From Her New Mexico Home, Karen Smoot Advocates for Fellow Patients With IPF

Trim and athletic her entire life, Karen Smoot—a nonsmoker—was still running triathlons in her early 60s. That’s why she was surprised when, in 2011, she began having trouble walking up to the fourth floor of the office where she worked.

Link to Article

ILD Pulmonary Care Outcomes Don’t Depend on Distance

Individuals in close proximity to care for interstitial lung disease (ILD) did not have significantly improved outcomes than those at a greater distance, based on data from more than 1600 individuals and presented at American College of Chest Physicians (CHEST) 2025 Annual Meeting.

Link to Article

Small changes in lung CT scans linked to declining lung function

Whether change in fibrosis on high-resolution CT is associated with near- and longer-term outcomes in patients with fibrotic interstitial lung disease (fILD) remains unclear, prompting a new study by researchers led by Matthew Koslow, M.D., of the Center for Interstitial Lung Disease, Division of Pulmonary and Critical Care Medicine at National Jewish Health in Denver, and colleagues.

Link to Article

Celebrating 25 years of the Pulmonary Fibrosis Foundation: driving awareness, research, and support

The Pulmonary Fibrosis Foundation (PFF) is marking a major milestone in 2025: 25 years of progress in improving the lives of those affected by pulmonary fibrosis (PF). Since its founding in 2000, PFF has become a leading voice in patient support, education, research funding, and advocacy.

Link to Article

PFF Urges Patients to Use Only FDA-Approved Oxygen Delivery Devices

The Pulmonary Fibrosis Foundation has issued a position statement on non-prescription supplemental oxygen. Patients living with pulmonary fibrosis should have a prescription for oxygen from their healthcare provider and should only use FDA-approved oxygen delivery devices.

Link to Article

PFF Urges Patients to Use Only FDA-Approved Oxygen Devices

The medical advisory board of the Pulmonary Fibrosis Foundation (PFF) has issued a position statement on non-prescription supplemental oxygen, advising the patient community to use only FDA-approved oxygen delivery devices as prescribed by their doctor.

Link to Article

PFF Issues Warning About Non-Prescription Supplemental Oxygen

The PFF warns that patients should not purchase an oxygen supply device without a prescription from a health care provider because doing so may lead to serious health problems. It also warns non-FDA approved oxygen delivery systems may not reliably deliver oxygen.

Link to Article

Pulmonary Fibrosis Foundation’s latest registry offers research opportunities

The PFF Community Registry collects self-reported data from patients, nonprofessional caregivers and biological family members via a secure online portal. Participation is voluntary.

Link to Article